Trial · NCT00311363
Results by group247
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 247
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced a Relapse During the Double-Blind Treatment Period | DB Placebo | 22.7 | percentage of participants | ||
| Percentage of Participants Who Experienced a Relapse During the Double-Blind Treatment Period | DB GEn 1200 mg | 9.4 | percentage of participants | ||
| Mean Change From Randomization to Week 36 (or End of Treatment) in the IRLS Rating Scale (IRLS) Total Score Using Last Observation Carried Forward (LOCF) | DB Placebo | Randomization | 5.3 | Standard Deviation 4.63 | points on a scale |
| Mean Change From Randomization to Week 36 (or End of Treatment) in the IRLS Rating Scale (IRLS) Total Score Using Last Observation Carried Forward (LOCF) | DB GEn 1200 mg | Randomization | 5.1 | Standard Deviation 4.20 | points on a scale |
| Mean Change From Randomization to Week 36 (or End of Treatment) in the IRLS Rating Scale (IRLS) Total Score Using Last Observation Carried Forward (LOCF) | DB Placebo | Week 36 | 9.2 | Standard Deviation 6.76 | points on a scale |
| Mean Change From Randomization to Week 36 (or End of Treatment) in the IRLS Rating Scale (IRLS) Total Score Using Last Observation Carried Forward (LOCF) | DB GEn 1200 mg | Week 36 | 7.0 | Standard Deviation 7.47 | points on a scale |
| Mean Change From Randomization to Week 36 (or End of Treatment) in the IRLS Rating Scale (IRLS) Total Score Using Last Observation Carried Forward (LOCF) | DB Placebo | Mean change from Randomization to Week 36 | 3.9 | Standard Deviation 6.49 | points on a scale |
| Mean Change From Randomization to Week 36 (or End of Treatment) in the IRLS Rating Scale (IRLS) Total Score Using Last Observation Carried Forward (LOCF) | DB GEn 1200 mg | Mean change from Randomization to Week 36 | 1.9 | Standard Deviation 7.01 | points on a scale |
Percentage of Participants Who Responded to Treatment Based on Scores on the Investigator-Rated Clinical Global Impression of Change (CGI-C) Scale as a Dichotomous Variable at Week 36 (DB Treatment Phase) Using LOCF | DB Placebo | 67 | percentage of participants | ||
Percentage of Participants Who Responded to Treatment Based on Scores on the Investigator-Rated Clinical Global Impression of Change (CGI-C) Scale as a Dichotomous Variable at Week 36 (DB Treatment Phase) Using LOCF | DB GEn 1200 mg | 75 | percentage of participants | ||
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB Placebo | Very much improved (score of 1) | 4 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB GEn 1200 mg | Very much improved (score of 1) | 10 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB Placebo | Much improved (score of 2) | 5 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB GEn 1200 mg | Much improved (score of 2) | 3 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB Placebo | Minimally improved (score of 3) | 12 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB GEn 1200 mg | Minimally improved (score of 3) | 15 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB Placebo | No change (score of 4) | 44 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB GEn 1200 mg | No change (score of 4) | 44 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB Placebo | Minimally worse (score of 5) | 14 | participants | |
| Number of Participants in Each Category of the Investigator-Rated CGI-C at Week 36 (DB Treatment Phase) Using LOCF | DB GEn 1200 mg | Minimally worse (score of 5) | 13 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00311363/results